Figure S16 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Q: What type of study is this?

This is a Quantitative Study study.

Nikola Knoll; Sarah Masser; Blanka Bordas; Richard Y. Ebright; Guangyan Li; Devishi Kesar; Eliana Destefanis; Nicholas Kania; Diego J. Rodriguez; Jayu Jen; Sydney E. Zagar; Caleb Mensah; Zixin Chen; Samuel J. Moffitt; Erhumuoghene M. Enakireru; Yao He; Baomou Feng; Mira K. Chokshi; Cyrus Y. Jin; Srivatsan Raghavan; William R. Sellers; Kathleen M. Mulvaney

doi:10.1158/0008-5472.30125760

Key Points

G2/M checkpoint pathways are significantly impacted by MTAP-targeted treatments.
Treatment with either ERK1/2 inhibitors or A/B/C-RAFi represses PRMT5 mRNA expression.
Discovery stems from a CRISPR-drug combinatorial screening process on MTAP-deleted cancer cells.
This analysis suggests potential new therapeutic strategies for cancer involving checkpoint modulation.

Implication

GSEA analysis reveals G2/M checkpoint affected by MTAP-targeting drugs, suggesting new cancer therapies.

Abstract

Figure S16. Differential GSEA pathway analysis shows G2/M checkpoint is impacted by MTAC-PRMT5i and PRMT5 mRNA is repressed by treatment with either ERK1/2i or A/B/C-RAFi.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knoll et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa588cd https://doi.org/10.1158/0008-5472.30125760

View at Publisher

Ask AI

Bookmark

Share

Figure S16 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S16 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading